A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors (NCT06963398) | Clinical Trial Compass
Not Yet RecruitingPhase 1
A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors
520 participantsStarted 2025-05-15
Plain-language summary
HS-10529 is an oral, highly selective, small molecular inhibitor of KRAS G12D. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10529 in KRAS G12D patients with advanced solid tumors.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* At least age of 18 years at screening.
* Patients of advanced solid tumor，who have progressed on or intolerant to standard therapy.
* With measurable lesion according to RECIST 1.1.
* Agree to provide fresh or archival tumor tissue.
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~1.
Exclusion Criteria:
* Previous or current treatment with KRAS G12D inhibitors.
* Uncontrolled pleural, ascites or pericardial effusion.
* Known and untreated, or active central nervous system metastases.
* History of other primary malignant tumors.
* Serious, uncontrolled, or active comorbidities.
* Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow oral medications.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The maximum tolerated dose (MTD) or maximum applicable dose (MAD)